(Q39537308)

English

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

scientific article published on 29 July 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

12 September 2017

phase III clinical trial

0 references

Brigitte Dréno

3

object named as

Brigitte Dréno

0 references

Matthew J Wongchenko

object named as

Matthew Wongchenko

15

0 references

Daniil Stroyakovskiy

object named as

Daniil Stroyakovskiy

9

0 references

object named as

Grant A McArthur

2

0 references

Paolo Antonio Ascierto

1

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

12 September 2017

20

object named as

Antoni Ribas

1 reference

Europe PubMed Central

12 September 2017

21

object named as

James Larkin

1 reference

Europe PubMed Central

12 September 2017

author name string

Victoria Atkinson

4

1 reference

Europe PubMed Central

12 September 2017

Gabrielle Liszkay

5

1 reference

Europe PubMed Central

12 September 2017

Anna Maria Di Giacomo

6

1 reference

Europe PubMed Central

12 September 2017

Mario Mandalà

7

1 reference

Europe PubMed Central

12 September 2017

Lev Demidov

8

1 reference

Europe PubMed Central

12 September 2017

Luc Thomas

10

1 reference

Europe PubMed Central

12 September 2017

Luis de la Cruz-Merino

11

1 reference

Europe PubMed Central

12 September 2017

Caroline Dutriaux

12

1 reference

Europe PubMed Central

12 September 2017

Claus Garbe

13

1 reference

Europe PubMed Central

12 September 2017

Yibing Yan

14

1 reference

Europe PubMed Central

12 September 2017

Ilsung Chang

16

1 reference

Europe PubMed Central

12 September 2017

Jessie J Hsu

17

1 reference

Europe PubMed Central

12 September 2017

Daniel O Koralek

18

1 reference

Europe PubMed Central

12 September 2017

Isabelle Rooney

19

1 reference

Europe PubMed Central

12 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 July 2016

1 reference

Europe PubMed Central

12 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

12 September 2017

17

1 reference

Europe PubMed Central

12 September 2017

1248-1260

1 reference

Europe PubMed Central

12 September 2017

9

1 reference

Europe PubMed Central

12 September 2017

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sex Steroid Hormone Receptors in Human Thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic score for patients with advanced melanoma treated with ipilimumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30122-X

1 reference

Europe PubMed Central

12 September 2017

release_rxlp4hvtqrajbifdkms6epcaza

0 references

1 reference

Europe PubMed Central

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39537308&oldid=1836829318"